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ABSTRACT OF THE DISSERTATION
Modeling HER2 mutations in Colorectal Cancer using a HER2 Transgenic Mouse Model and
Gastrointestinal Organoids
by
Elisa Murray
Doctor of Philosophy in Biology and Biomedical Sciences
Biochemistry
Washington University in St. Louis, 2020
Professor Ron Bose, Chair

Amplification or mutations in members of the epidermal growth factor receptor family,
such as HER2, have been identified in several human diseases. In particular, mutations in the
intracellular kinase domain have been identified in breast, colon, and lung cancers. The Cancer
Genome Atlas has identified HER2 mutations or gene amplification in seven percent of colon
cancer patients. These mutations are well known to promote enhanced cell growth and
transformation of colon cancer cell lines. Previous studies have found HER2 mutations to confer
anchorage independent growth and activation of downstream signaling pathways such as MAPK.
Although HER2 mutations have been extensively characterized using cell line overexpression
models, the role of HER2 alterations on tumorigenesis, particularly in the gastrointestinal tract,
has not been studied. In this thesis, the role of an activating HER2 mutation, V777L, was
examined using small intestinal organoids, a three-dimensional culture model. Additionally, we
also sought to explore the cooperative role of both HER2 and APC mutations. Using this model,
we showed distinct morphological changes in intestinal organoids upon expression of either

x

HER2 or APC alone, or in combination. Furthermore, in vivo expression of HER2V777L driven by
the Lgr5-Cre recombinase showed increased intestinal hyperplasia throughout the small intestine
and the loss of distinct intestinal cell populations. This work is the first characterization of an
activating HER2 mutation in the intestine using a transgenic mouse model and a threedimensional culture model. Lastly, we show that in vitro expression of oncogenic mutations such
as KRAS in HER2 mutated colon cancer cell lines confers reduced sensitivity to a HER2targeted therapeutic, neratinib, which further illustrates the impact of multiple oncogenic
mutations on cell growth. Taken together, we illustrate the role of HER2 and co-occurring
mutations on the intestinal epithelium as well as the effect of HER2 and KRAS co-occurring
mutations on colon cancer cell line inhibitor sensitivity and downstream signaling pathways.

xi

Chapter 1: Introduction

1

1.1 Summary of EGFR family of receptor tyrosine kinases
The epidermal growth factor receptor (EGFR) is a member of a receptor tyrosine kinase family
comprised of the HER2, HER3, and HER4 receptor tyrosine kinases (1). In particular, epidermal
growth factor, was first discovered by Stanley Cohen as a peptide that accelerated eyelid opening
in newborn mice (2). The structure of these receptor tyrosine kinases includes a cytoplasmicligand binding domain, a transmembrane region, and an intracellular region containing the kinase
domain (Figure 1.1A). Activation of these receptors is conferred by ligand-mediated
dimerization of EGFR family members (3). Specifically, ligand binding to subdomains I and III
triggers a conformational change from the tethered to extended conformation allowing the
dimerization arm in subdomain II to be exposed for interaction with other EGFR family
members (4) (Figure 1.1B). Following dimerization, kinase domain activation facilitates
phosphorylation of the cytoplasmic tail of both receptors and allows for binding of effector
proteins for downstream signaling pathway activation to promote enhanced cell growth,
proliferation, and cell-cycle progression (5).
EGFR, has six known ligands including EGF, TGF-α, amphiregulin, epiregulin, as well as others
(6). Neuregulins, such as NRG1 and NRG2 bind to HER3 and HER4, and NRG3 and NRG4
exclusively bind to HER4 (7). In contrast, no known ligand has been identified for HER2 (8).
Additionally, HER3 has minimal kinase activity in relation to the other EGFR family members
and forms hetero-dimers with other EGFR family members, such as HER2, to mediate
intracellular signaling (9). In addition to activation in a ligand-dependent manner, EGFR family
members can also be activated via overexpression or mutation in a ligand-independent manner.
Mutation or overexpression of EGFR family members has also been reported in several cancers,
such as breast, lung, and colon cancer (10-11).
2

Figure 1.1 Structure of the EGFR family of Receptor Tyrosine Kinases. This figure is
adapted from Croucher, D., 2016 (4).
1.2 Role and significance of EGFR family members in cancer
Human tumors have been found to overexpress EGFR and other related family members, and
expression of these receptors often results in a more aggressive disease phenotype (12). In
addition, gene amplification, kinase domain mutations, and in-frame deletions of EGFR family
members have also been identified in several cancer types (13-15). These alterations promote
constitutive activation of downstream signaling pathways and confer enhanced tumor growth and
development. For example, in non-small cell lung cancer (NSCLC), point mutations in the kinase
domain of EGFR, such as L858R (38%) and in-frame deletions or insertions in exon 20 (6%)
have been identified (16-17). Mutations in the kinase domain have also been shown to promote
oncogenic properties in vitro and confer resistance to EGFR tyrosine kinase inhibitors (18-19).
3

Similarly, HER2 kinase domain mutations, such as in-frame exon 20 insertions, were identified
in 1-4% of NSCLCs (20). The HER2 G776YVMA insertion mutation, for example, enhanced
tyrosine kinase activity and conferred resistance to EGFR tyrosine kinase inhibitors using cell
culture based assays (21). In addition, to somatic mutations, gene amplification of EGFR or
HER2 occurs in 62% and ~30% of NSCLCs, respectively (22-23). Gene amplification of EGFR
has also been found to result in response to EGFR tyrosine kinase inhibitors (24). In summary,
over-expression and mutation of EGFR and HER2 in NSCLCs serve to hyper-activate downstream signaling pathways and confer resistance to targeted therapies.
EGFR family members such as HER2 and HER3 are also over-expressed in other cancer types.
Specifically, HER2 and HER3 are over-expressed in 20% and 50-70% of breast cancer cases,
respectively (25-26). HER2 and HER3 form a potent heterodimer and mediate downstream
signaling to enhance tumor growth and development. Additionally, overexpression of HER2 and
HER3 are associated with worse clinical outcomes and reduced overall survival in breast cancer
patients (27-28). HER2 amplified breast cancers, however, have increased sensitivity to targeted
chemotherapeutics, such as Herceptin. In addition to breast cancer, HER2, HER3, and other
EGFR family members are widely overexpressed in ovarian, prostate, bladder, gastric, and
colorectal cancers and are associated with poor disease outcomes (29-32).
1.3 Prevalence and role of HER2 mutations in colon cancer
The Cancer Genome Atlas (TCGA) has identified somatic mutations or gene amplification of
HER2 in 7% of colorectal patients (33). Several of these mutations are identical to those
identified in breast cancer patients. For example, the HER2 V842I and V777L mutations have
been identified in both breast and colorectal cancer. These mutations were found to cluster in
4

several hotspots throughout the extracellular domain, at residues 309-310, and 755-781 in the
kinase domain (Figure 1.2). Previous characterization of these mutations in breast and lung
cancer has revealed that these mutations enhance downstream signaling pathways and confer
oncogenic phenotypes (34-36).

Figure 1.2 Schematic of HER2 somatic mutations in 12 colon cancer patients. This figure is
adapted from Kavuri, S. (2015).
1.4 In vitro characterization of HER2 activating mutations
Several studies have explored the role of HER2 mutations on cell growth and proliferation using
colon or breast cell lines. Specifically, overexpression of wild-type HER2 and five different
HER2 mutations (HER2 V777L, V842I, L755S, L866M, and S310F) into immortalized colon
epithelial cells were shown to increase phosphorylation of HER2, activate downstream signaling
pathways, and enhance colony formation in soft-agar assays (37). In particular, the L755S,
V777L, and L866M mutations increased the number of colonies in soft-agar, whereas, the V842I
mutation produced the least number of colonies in this assay. The strength and observed
phenotype of these mutations in vitro can therefore vary depending on the location and amino
acid change of each mutation. Overall, these mutations were found to be activating mutations
using in vitro experimental assays.
Similar studies of HER2 mutations in non-transformed mammary epithelial cells, MCF10A, also
showed that these mutations confer activation of downstream signaling pathways. However,
5

knock-in of a single copy of these mutations using adeno-associated virus in breast epithelial cell
lines (MCF-10A and MCF7) only identified the HER2 V777L mutation to be transforming,
indicating that the expression level of HER2 in cell lines can influence observed phenotypes
(35).
Due to the striking in vitro phenotype of these mutations, biological assays have also been
utilized to further determine how HER2 mutations can confer different biological effects. For
example, in vitro kinase assays have been utilized to compare the strengths of various mutations.
Using these assays, the HER2 V777L, D769H, and V842I mutations were found to have higher
activity relative to wild-type (36). Interestingly, among the three mutations that were tested, the
V777L mutation had 20 fold higher activity compared to the V842I mutation, which only had 3
fold-higher activity relative to WT. These differences in kinase activity underscore important
distinctions between the different kinase mutations. Additionally, the strength of these mutations
has also been found to have distinct effects on sensitivity to HER2 based therapeutics.
1.5 Pre-clinical data on HER2 mutations and inhibitor sensitivity
Studies of the activating HER2 mutations in breast cancer cell lines determined that several
HER2 mutations are sensitive to dual HER2/EGFR tyrosine kinase inhibitors, such as neratinib
(36). Unlike monoclonal antibodies, such as trastuzumab that bind to the extracellular domain of
HER2, tyrosine kinase inhibitors block kinase activity and subsequent phosphorylation.
However, the HER2 L755S mutation was found to be resistant to another HER2 TKI, lapatinib.
The lack of sensitivity to this therapeutic is due to the proximity of the mutation to the binding
site of the drug (38). Similarly, the introduction of HER2 mutations in colon cancer cell lines
with intrinsic sensitivity to EGFR monoclonal antibodies, such as cetuximab, conferred
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resistance to these therapies (37). Although these cell lines were resistant to EGFR targeted
therapy alone, these cell lines were sensitive to neratinib.
Studies by Kloth et al have also explored HER2 mutations and their sensitivity to HER2 targeted
therapy using colon cancer cell lines with endogenous HER2 mutations. Specifically, the colon
cancer cell lines, CW-2 and CCK-81, cell lines, which express the endogenous HER2 L755S and
L720P mutations, respectively, have also been shown to be sensitive to afatinib in the nanomolar
range (39). The CW-2 cell line, however, is resistant to lapatinib due to the L755S mutation, as
mentioned previously. Bertotti et al has also identified genetic alterations in EGFR family
members, such as HER2, to be a mechanism of resistance to EGFR therapeutics, further
supporting the ideal that alterations in HER2 can alter sensitivity to antibodies commonly used to
treat colon cancer patients (40).
As mentioned previously, EGFR targeted therapies are often commonly used to treat metastatic
colorectal cancer patients. However, common mechanisms of resistance to EGFR therapeutics
include activation of downstream signaling effectors such as KRAS, PIK3CA, BRAF, etc (41).
Mutations in the Ras/Raf/ MAPK pathway lead to hyper-activation of cell signaling pathways,
rendering therapeutics targeting EGFR, such as cetuximab, ineffective. Additionally, a basket
trial studying HER2 mutations across multiple tumor types also determined that, unlike HER2
mutated breast cancer patients, colorectal cancer patients possessing HER2 mutations are also
resistant to neratinib (42), suggesting that multiple mechanisms could be responsible for the lack
of response to therapy.
1.6 Role of EGFR family members on intestinal homeostasis
In addition to their role in cancer, EGFR family members also maintain homeostasis of the
intestinal epithelium. The intestinal epithelium is comprised of crypts of Lieberkuhn and villi,
7

which function in the absorption of food. The crypts contain intestinal stem cells and Paneth cells
that are interspersed between stem cells at the base of the crypt (Figure 1.3). Crypt-base
columnar stem cells reside at the base of the crypt and give to transit-amplifying cells. The
transit-amplifying cells terminally differentiate into several epithelial cell types, such as goblet
cells that secrete mucus and are located along the villus (43). Other differentiated cell types
include absorptive enterocytes, chemosensory tuft cells, and hormone-releasing enteroendocrine
cells. Paneth cells, however, migrate downward
towards the crypt base and produce Wnt, EGF and
other growth factors for maintenance of the stem
cell niche (44). Proliferation is also typically
restricted to the crypt and differentiation occurs
along the villus.
Figure 1.3 Crypt-villus structure and intestinal cell types. This figure is adapted from
Murray, E. (2020-CMGH Submission)
Additionally, expression of growth factor receptors control intestinal cell proliferation, growth,
and wound-healing (45-48). EGFR signaling in the gut is responsible for regulating growth,
migration, survival, intestinal development, and serves as a gastrointestinal protective factor via
binding to EGFR (49-53). Previous studies have also determined that EGF expression enhances
villus height and crypt depth, implicating a role for EGF on intestinal growth and development
(54). Due to the role of EGFR on intestinal barrier protection and wound-healing, loss of EGFRmediated signaling often results in inflammatory disorders such as colitis and several studies
have explored the role of EGFR family members on the intestinal epithelium following injury.
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Studies exploring the functional role of EGFR have identified a protective role for EGFR
signaling in spontaneous colitis models (55). EGFR inactivation in these models resulted in
accelerated colitis, suggesting that EGFR plays a role in the initiation and progression of colitis
associated disorders. In contrast, studies of the role of HER2 on the intestinal epithelium are
somewhat limited due to embryonic lethal cardiac defects caused by deletion of HER2 (56).
Epithelial expression of HER2 is required for short-term recovery from colitis and knockout of
HER2 in intestinal epithelial cells results in hyper-proliferation and apoptosis (57). Similarly,
knockout of HER3 also produces embryonic lethal cardiac defects, however HER3 expression
has also been found to play a protective role in the intestinal epithelium following injury (57).
The role of HER4 on the intestinal epithelium, however, is less well characterized. Expression of
HER4 in the intestinal epithelium by NRG4 administration hyperactivates the PI3K/Akt pathway
and protects the intestinal epithelium from DSS-mediated colitis (58).
1.7 Role of EGFR family members in colorectal tumorigenesis
Several studies have also explored the role of EGFR family members on colorectal
tumorigenesis. EGFR, HER2, and HER3 are commonly over-expressed in intestinal cancers (5961). In particular, EGFR expression is increased in colonic pre-cancerous lesions and tumors
(62-63). Animal models exploring the role of EGFR on tumor initiation and development have
determined that inactivation of the EGFR kinase domain using Egfrwa2 mice resulted in a 90%
reduction of intestinal polyp formation, suggesting that EGFR is required for intestinal tumor
development (64). In contrast, HER2 overexpression models for colon cancer have not been
developed outside of our laboratory. Models exploring the role of HER2 overexpression on
breast epithelium, however, have determined that overexpression of wild-type HER2 (MMTVneu) confers hyperplasia and oncogenic transformation of the epithelium (65). Lastly, intestine
9

specific deletion of HER3 also results in a near complete absence of intestinal tumors using the
Apcmin mouse model, which develops intestinal tumors due to loss of the Apc gene, suggesting
that HER3 plays a crucial role in tumor initiation (66).
1.8 Summary of existing colon cancer mouse models
Several mouse models for colorectal cancer have been developed that explore the role of cooccurring mutations, such as KRAS and APC on tumorigenesis. KRAS mutations, for example,
are present in 40-50% of colorectal adenomas and carcinomas, whereas mutations in APC are
present in 60-80% of colorectal carcinomas (67-68). For example, studies examining the role of
KRAS and APC mutations on tumorigenesis have determined that expression of KRAS alone did
not initiate adenoma development, however, expression of KRAS and APC mutations together
accelerated tumorigenesis (69). Mechanisms underlying this phenotype were attributed to
activation of the Mapk signaling pathway and increased expression of Wnt/B-catenin target
genes.
Other studies have examined the role of several colorectal cancer driver genes, such as APC,
KRAS, TRP53, and TGFBR2 on malignant progression of colon cancer. Using mouse models
expressing APCΔ716, KRASG12D, TRP53R270H, and TGFR2-/- in various combinations, the effect
of each mutation on polyp development was determined. Specifically, the combination of APC
and KRAS mutations lead to an increase in the number of small polyps relative to each mutation
alone (70). Additionally, KRAS activation also promoted formation of liver metastases when
combined with APC and TGFBR2 mutations (70). Similarly, studies analyzing APC, KRAS, and
TP53 on colorectal cancer metastasis, identified a crucial role for KRAS in driving metastasis via
up-regulation of TGF-β signaling (71). Taken together, these studies illustrate the role of several
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colorectal cancer driver genes on adenoma to carcinoma progression and metastasis and the
underlying signaling pathways involved in transformation.
1.9 Overview of 3D intestinal organoid culture models
Small intestinal epithelial cells can be cultured in Matrigel to form three-dimensional structures,
named organoids, which morphologically resemble the crypt and villus of the small intestinal
epithelium. These organoids self-organize into budded structures, resembling the crypts, and
contain a central lumen lined by the villus domain (Figure 1.4). Studies by Sato et al. have
established culture conditions for mouse-derived organoid cultures that include growth factors
needed for survival, such as EGF, Noggin, R-spondin, etc (72). EGF enhances proliferation in
organoid cultures, Noggin inhibits bone morphogenic protein to enhance crypt development, and
R-spondin induces crypt hyperplasia (73-75). Additionally, lineage tracing analysis of crypts
isolated from Lgr5-EGFP-ires-CreERT2 mice revealed that single Lgr5 positive cells can
generate crypt-villus structures in vitro (76). Organoids derived from single stem cells also
contain all of the differentiated cell types found within the intestinal epithelium such as Paneth,
goblet, and enteroendocrine cells. Lastly, studies exploring the role of EGFR family members on
organoid morphology have determined that loss of Lrig, a negative regulator of EGFR signaling,
results in growth-factor independence in organoid cultures grown in media lacking EGF (77). As
a result, intestinal organoid culture can be useful in determining the role of particular genetic
alterations on organoid growth and morphology.
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1.10 Conclusion
In conclusion, the role of EGFR family of receptor tyrosine kinases has been extensively
characterized in several cancer types and their role in enhancing proliferation, cell growth, and
migration has been well established. Additionally, EGFR family members play crucial roles in
maintaining intestinal epithelial homeostasis and tumorigenesis. In particular, our lab and others
are interested in the role of HER2, an EGFR family member, on colorectal cancer. In vitro
characterization of HER2 mutations, such as HER2 V777L, has identified that HER2 mutations
located throughout the kinase domain, are activating mutations that enhance MAPK downstream
signaling pathways in colon cancer cell lines. Although HER2 mutations have been characterized
in vitro, our knowledge of their role on intestinal epithelial homeostasis, crypt-villus architecture,
and colorectal tumorigenesis remains sparse. In particular, studies exploring the role of the
activating HER2 mutation, HER2V777L in vivo would allow us to better understand the
developmental mechanisms underlying intestinal tumorigenesis and gain further insight into how
intestinal cells, such as Paneth cells, are changed by expression of HER2V777L. In addition, the
role of an activating HER2 mutation has not been previously characterized using a transgenic
mouse model or an intestinal organoid model. As a result, the next two chapters of this thesis
will address the following two questions that remain unanswered in the field: (1) What are the
morphological changes associated with in vitro expression of HER2V777L alone or in combination
with APC in intestinal organoids, (2) How does in vivo expression of HER2 and APC mutations
impact intestinal epithelial proliferation, crypt-villus architecture, expression of secretory cells,
and tumor formation? Lastly, the role of HER2 and co-occurring mutations on therapeutic
resistance to HER2 targeted therapies will also be explored in the fourth chapter of this thesis.
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Chapter 2: Deciphering Novel Colorectal Cancer Mutations using
Gastrointestinal Organoids

13
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2.2 Abstract
Mutations or amplification of HER2 has been identified in 7% of colorectal cancer (CRC)
patients and are known to result in activation of downstream signaling pathways such as MAPK.
In addition to HER2 mutations, colorectal cancer patients also possess co-occurring mutations in
APC, a tumor suppressor gene highly mutated in CRC. Using an intestinal organoid model
derived from a HER2V777L and APCmin double mutant mice, we determined that HER2V777L
expression alone increased proliferation and activation of downstream signaling pathways. In
contrast, the expression of both HER2 and APC mutations in the intestinal organoid model
increased proliferation, conferred a distinct morphological phenotype, and activated Wnt-target
genes. Our experiments provide novel characterization of HER2V777L expression on both
intestinal epithelial homeostasis and proliferation.
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2.3 Introduction
Colorectal cancer (CRC) is initiated by the loss of a tumor suppressor gene, APC, and
subsequent alterations in oncogenes such as KRAS, facilitate the adenoma to carcinoma
transition (78). This step-wise model of tumorigenesis has been well described and several
studies have shown the relevance of oncogenes in CRC disease development and progression to
metastasis. APC mutations, for example, are present in 90% of colorectal cancer patients and are
often the first “hit” that initiates the transition from the normal intestinal epithelium to an
adenoma (68). Mutations in APC also hyper-activate Wnt signaling and disrupt intestinal
homeostasis. Genetically engineered mouse models such as the APCmin mice, develop several
small intestinal polyps, and have been extensively utilized to characterize the role of APC gene
loss on CRC development (79-81). In addition to alterations in tumor suppressor genes, recent
studies have also identified the presence of mutations or alterations in a receptor tyrosine kinase
gene, HER2, in CRC patients.
In vitro characterization of HER2 mutations has identified several activating mutations such as
V777L, V842I, and L755S that promote anchorage independent growth and activate intracellular
signaling pathways in colon cancer cell lines (37). Additionally, a recent basket trial of HER2
and HER3 mutant cancers by Memorial Sloan Kettering demonstrated that HER2 mutant colon
cancer patients possessed co-occurring mutations in APC (42). The prevalence of HER2 and
APC mutations was also illustrated in studies by the Dana Farber Cancer Institute using 619
colorectal cancer patients (82). Given the well-defined role of APC mutations in CRC
progression and development, we reasoned that HER2 and co-occurring mutations in APC would
hyper-activate downstream signaling pathways and induce changes in the intestinal epithelium
relative to HER2 or APC mutations by themselves. Furthermore, the role of HER2 and co16

occurring mutations on intestinal cell development has not been extensively characterized and
could aid in the development of novel treatment options for HER2 mutated colon cancer patients.
To study the effect of both HER2 and APC mutations on the intestinal epithelium and various
intestinal cell types, we utilized an intestinal organoid model. Specifically, we utilized intestinal
organoids derived from HER2V777L transgenic (Tg) and APCmin; HER2V777L Tg mice. Using the
intestinal organoid model, we determined that expression of HER2V777L alone conferred
increased budding and expression of HER2 and APC mutations, when combined, resulted in
activation of Wnt signaling genes. Overall, we utilized the intestinal organoid model to illustrate
the role of HER2V777L and additional genetic alterations on proliferation, organoid morphology,
and downstream signaling pathways.
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2.4 Methods
Intestinal crypt culture
Isolation of crypts from the jejunum of HER2V777L Tg littermate mice were performed as
described (72). Briefly, four to six centimeters of medial jejunum were isolated from HER2V777L
Tg mice. The intestine was cut lengthwise and rinsed quickly in ice-cold PBS. Intestinal tissues
were vortexed in cold PBS in a 50 mL conical tube to clean lumen contents. To loosen mucus,
intestinal tissues were vortexed in 10 mL of calcium and magnesium free-Hank’s Balanced Salt
Solution (CMF-HBSS) with 1 mM N-acetyl cysteine (NAC) for 15 seconds for a total of 2
minutes in a 15 mL conical tube. Intestinal tissues were incubated with 10 mL of ice cold CMFHBSS containing 10 mM EDTA and 1 mM NAC on a rotator for 45 minutes. Following the 45
minute incubation, the conical tube containing intestinal tissues was vortexed for 30 seconds
(rest 30 seconds on ice) for 8 minutes total. The vortexed solution was then poured filtered using
a 70 µm BD filter. Eluates were centrifuged for 1 min at 100 x g and the supernatant was
removed. Intestinal crypts were resuspended in basal culture media and 10 uM ROCK inhibitor
and spun at 100 x g for 2 minutes.
Isolated intestinal crypts were embedded in Matrigel (BD Biosciences) and seeded in 6-well
plates. The cells were overlaid with 2 mL/well basal culture medium (advanced Dulbecco’s
modified Eagle medium/F12 supplemented with penicillin/streptomycin, 10 mmol/L HEPES,
Glutamax, 1 × N2, 1 × B27 [all from Thermo Fisher Scientific], and containing EGF (Sigma),
noggin, and Rspo1 (Noggin and R-spondin conditioned media were a gift from Blair Madison).
Individual polyps from the distal small intestine of APCmin; Her2 Tg were picked and resuspended in Hanks Balanced Salt Solution (HBSS-Invitrogen) and incubated with 0.5 M EDTA
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(Sigma) for 30 minutes at 4°C. Crypts were centrifuged at 500 x g for 45 seconds and the pellet
was re-suspended in 80% Matrigel/20% ENR media.
Complete crypt culture (ENR) medium
Basal culture medium
mEGF (500 ug/mL)
0.5 M N-acetylcysteine
N2 Supplement (100x)
B27 Supplement (50x)
293TCT-NtRiP CM (~20x)

-add to final volume
final= 50 ng/mL
final= 1 mM
final= 1x
final= 1x
final=5%

23 mL
2.5 µL
50 µL
250 µL
500 µL
1.25 mL

Basal culture medium
Advanced DMEM/F12 + 2 mM Glutamax + 10 mM HEPES + 1% P/S
Adenoviral-Cre mediated infection
Adenovirus Cre recombinase-mCherry was obtained from the University of Iowa (Ad5CMVCremCherry) and obtained at stock concentration of 5 x 1010 pfu/ml). Adenovirus was added to
freshly isolated crypts suspended in 250 µL of 80% Matrigel/ 20% ENR (EGF, Noggin, Rspondin,). The final concentration of virus used was 2.4 x 108 pfu/mL. Organoids were seeded in
a 6 well plate and overlayed with 2 mL of ENR media. mCherry fluorescence was detected 72
hours after infection using a fluorescence microscope.
Immunofluorescence
Organoids were seeded in 3 wells of a 12 well plate and grown for 5 days in ENR media. The
organoids were fixed in 1 mL of 10% buffered formalin for 1 hour at 4°C. The organoids were
scraped from each well and dissociated using Cell Recovery Solution (Corning) at 4° for 30
minutes on a rotator and transferred to 1.5 mL Eppendorf tubes. The organoids were blocked for
1 hour in blocking solution overnight at 4° (5% goat serum, 0.5% Triton-x 100 in PBS).
Organoids were incubated for 1 hour with primary antibodies (rabbit HER2, Cell signaling,
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29D8) in blocking solution. Organoids were then washed three times with PBS and incubated
with the secondary antibody (Alexa Fluor 488, Goat anti-rabbit, Thermo Fisher) for 4-5 hours at
room temperature. Lastly, organoids were incubated with DAPI for nuclear staining (1:1000,
Thermo Fisher). This protocol is adapted from Strubberg et al (83).
Fixed frozen sections of intestinal organoids
Organoids were grown in 3 wells of a 12 well-plate, scraped and dissociated using Cell Recovery
solution (Corning) for 30 minutes at 4°C and transferred to 1.5 mL Eppendorf tubes. Organoids
were incubated in 1 mL of 4% PFA overnight. After removing the PFA, 1 mL of 10% sucrose
(Sigma) was added to each Eppendorf tube containing the organoids. The sucrose solution was
removed and replaced with fresh sucrose after 4 hours, and organoids were spun down at 300
rpm. OCT (VWR) was added to each organoid pellet after removing the sucrose solution, and the
OCT/organoid mixture was added to a cryomold block. Blocks were stored at -80°C until
sectioning. Sections were made on a cryostat and placed on uncharged slides for
immunohistochemistry.
Immunohistochemistry of fixed frozen sections
For histology, unstained slides were stained for the indicated antibodies via
immunohistochemistry (Department of Immunology and Pathology, Washington University
School of Medicine). Immunohistochemistry was performed by a standard protocol on Ventana
automated stainer (Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval was
performed for for KI-67 2 ug/mL (rabbit monoclonal, clone 30-9)(Ventana) with CC1 buffer
(Cell Conditioning 1; EDTA-based buffer pH 8.0, Ventana).
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Isolation of organoid lysates and western blotting
Organoid lysates were prepared as follows: Organoids were seeded in 3 wells of a 12 well plate
and grown in ENR media for 5 days. Organoids were scraped from the 12 well plate and
dissociated with 1 mL of Cell Recovery solution (Corning) for 30 minutes at 4°C. Organoids
were spun down at 500 x g, re-suspended in 50 uL of RIPA buffer, and sonicated for 90 seconds.
Lysates were spun down at 13,000 rpm for 5 minutes and the supernatant was transferred to a
new Eppendorf tube. Lysates were boiled for 5 minutes at 95°C and stored in -20. Western
blotting was performed as described (37).
Quantitative Reverse Transcription (RT)-PCR (qRT-PCR)
RNA was isolated from intestinal organoids and 2 ug of RNA were reverse transcribed into
cDNA using the cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). qRTPCR was performed with a ABI Prism 7300 Sequence Analyzer using SYBR green fluorescence
probes. Quantification cycle (Cq) of genes of interest were normalized to the average Cq of actin
and expressed as relative mRNA levels. Primer sequences are listed below (5’ to 3’).
Primer name

Primer sequence

c-Myc F
c-Myc R
Actin F
Actin R

CACACAACGTCTTGGAACGT
CGTCTGCTTGAATGGACAGG
TTGCTGACAGGATGCAGAAG
ACATCTGCTGGAAGGTGGAC
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2.5 Results
HER2 and APC mutations activate downstream signaling pathways and confers
morphological changes
To determine the role of HER2V777L expression on downstream signaling pathways and overall
organoid morphology, we utilized intestinal organoids generated from a HER2V777L transgenic
(Tg) mouse generated via TALEN based gene editing (Figure 2.1). HER2V777L Tg derived mouse
organoids were treated with Adenovirus-Cre recombinase (AdCre) to excise the Lox-STOP-Lox
cassette and induce expression of the transgene. To confirm that HER2 was expressed in our
organoid cultures, we stained for HER2 via immunofluorescence using a HER2 primary
antibody and an Alexa Fluor 488 secondary antibody. Immunofluorescence confirmed HER2
expression in all of the organoid cultures treated with AdCre (Figure 2.2). In contrast, intestinal
organoid cultures not treated with AdCre possessed low levels of basal HER2 expression.
Next, we examined signaling pathway changes induced by expression of HER2V777L. We found
that expression of HER2V777L alone activated phosphorylation of HER2 and downstream
signaling proteins such as MAPK (Figure 2.3). Additionally, we generated intestinal organoids
from APCmin and HER2V777L Tg mice double mutant mice (APCmin; HER2V777L Tg), at 16 weeks
of age from intestinal polyps. Similarly, expression of HER2 in the APCmin; HER2V777L Tg
organoids also activated phosphorylation of HER2 and MAPK downstream signaling (Figure
2.3). As a result, we validated our intestinal organoid model and confirmed that expression of
HER2V777L in our organoid model activates downstream signaling pathways.
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Figure 2.1 Design of HER2V777L transgenic mice and HER2V777L derived organoids.

Figure 2.2 HER2 expression in organoid cultures via immunofluorescence. Organoid lines
were treated with AdCre and assayed for immunofluorescence one week after infection to detect
HER2 expression. Whole-mount representative images are shown. Scale bars are 500 µm.

Figure 2.3 Western blot of HER2V777L Tg and APCmin; HER2V777L Tg organoid lysates.
Western blot analysis of organoids derived from B6 mice (WT) and intestinal organoids treated
in the presence and absence of AdCre (1 week after infection).
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HER2V777L expression confers enhanced budding and growth-factor independence
We next determined whether expression of HER2 or APC mutations alone or in combination
resulted in morphological changes in the organoid cultures. Expression of HER2V777L alone was
found to enhance budding of intestinal organoids in EGF, Noggin, R-spondin (ENR) media by
2.5-fold, relative to organoids that were not treated with AdCre (non-HER2V777L expressing)
(Figure 2.4A-B). Furthermore, withdrawal of EGF in the HER2V777L Tg organoids conferred
growth factor independence in the HER2V777L Tg AdCre treated organoids as observed by
enhanced organoid budding in EGF-free media relative to ENR media (Figure 2.4A-B).
Interestingly, expression of both HER2V777L and APC mutations conferred a distinct
morphological change and APCmin; HER2V777L Tg organoids possessed a 10-fold increase in the
number of budded structures relative to APCmin only organoids (Figure 2.5A-B). The budded
structures observed also contrasted the normal cyst-like morphology of APCmin derived
organoids.
To determine whether the enhanced budding phenotype observed in the HER2V777L Tg organoids
was due to increased proliferation, we utilized immunohistochemistry staining for Ki-67.
HER2V777L expression conferred a rapid budding phenotype with Ki-67 positive cells located
prominently within each bud (Figure 2.6). Additionally, expression of HER2V777L in the APCmin;
HER2V777L Tg organoid cultures resulted in expanded proliferation outside of the budded
regions, which was not observed in control organoids (Figure 2.6). Taken together, HER2V777L
expression enhances proliferation of intestinal organoid cultures and HER2 and APC mutations,
when combined, expand proliferation outside of the crypt.
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Figure 2.4 Morphology of HER2V777L Tg organoids (A) Brightfield images of HER2V777L Tg
intestinal organoids grown in ENR media and media lacking EGF for 5 days. (B) Quantification
of average number of buds per organoid in ENR and no EGF media. Scale bars are 500 µm.
Representative data from 3 independent experiments. ∗P < .05; ∗∗P < .01 by one-way ANOVA.
n.s., not significant.

Figure 2.5 Morphology of APCmin; HER2V777L Tg organoids (A) Brightfield images of
APCmin; HER2V777L Tg organoid cultured in ENR media for 5 days and (B) average number of
budded or non-cystic structures in APCmin; HER2V777L organoids. Scale bars are 500 µm.
Representative data from 3 experiments.∗∗∗P < .001 by Student t test.

25

Figure 2.6 IHC staining for Ki-67 in HER2V777L Tg and APCmin; HER2 Tg organoids.
Representative images of Ki-67 staining of fixed frozen organoid sections grown in ENR media
for 4 days. Scale bars are 500 µm.
Activation of Wnt signaling pathway changes HER2V777L Tg organoid morphology
Due to the profound budding phenotype observed in the HER2V777L-expressing organoid
cultures, we assessed whether Wnt activation would revert the observed budding phenotype. The
intestinal organoids were treated with a GSK-3β inhibitor, Chiron99021, to determine whether
Wnt activation reduces budding and confers a cyst-like morphology in the HER2V777L Tg
organoids. Treatment of the organoid lines with 4 uM of Chiron99021 for 3 consecutive passages
resulted in a 4.6-fold decrease in the number of buds in HER2V777L Tg expressing organoids
relative to a 5.8-fold change in non-HER2V777L expressing organoids (Figure 2.7A-B). These
differences were likely due to the enhanced budding phenotype observed in the HER2V777L Tg
organoid cultures. Additionally, repeated passage of the organoids in media containing
Chir99021 conferred a cyst-like morphology and the HER2V777L Tg organoids failed to bud in
this media condition (data not shown).
Expression of HER2V777L confers resistance to MEK inhibition
To examine potential mechanisms underlying the enhanced proliferation and budding observed
in the HER2V777L organoid cultures, we examined cell proliferation changes after treatment with
a MEK inhibitor, TAK-733. Given the enhanced MAPK signaling observed in the HER2V777L Tg
expressing cultures, we hypothesized that HER2V777L expression would confer resistance to
TAK-733. After treatment with TAK-733 for 5 days, HER2V777L Tg AdCre organoids possessed
decreased drug sensitivity (9.5-fold) relative to non-HER2V777L expressing organoids (Figure
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2.8). Additionally, APCmin; HER2V777L Tg AdCre organoids possessed a similar sensitivity to
TAK-733 as HER2V777L Tg AdCre organoids, As a result, we determined that HER2V777L confers
enhanced growth in a MEK independent manner and other signaling pathways likely contribute
to the phenotype observed.

Figure 2.7 GSK3β inhibitor treatment of HER2V777L Tg and APCmin; HER2V777L Tg
organoids. (A) Morphology of HER2V777L Tg organoids 5 days after treatment with Chir99021
and (B) Quantification of average bud number per organoid after Chir99021 treatment. Scale
bars are 500 µm. Representative data from 3 independent experiments. ∗P < .05; ∗∗∗P < .001 by
one-way ANOVA. ns., not significant.

Figure 2.8 TAK-733 dose response of HER2V777L Tg and APCmin; HER2V777L Tg organoids
Percent cell growth of indicated organoid lines after treatment with TAK-733 for five days as
measured via alamar blue assay.
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HER2 and APC mutations enhance activation of Wnt-target genes
We also sought to examine whether HER2V777L expression conferred enhanced signaling of Wnttarget genes give the cross-talk associated with EGFR family members and the Wnt-signaling
pathway (84). Additionally, APC mutations result in beta-catenin translocation to the nucleus
and expression of Wnt target genes, such as c-Myc (85). Interestingly, expression of HER2V777L
alone did not confer enhanced expression of c-Myc relative to untreated organoids (Figure 2.9).
However, c-Myc expression was enhanced by 2-fold in APCmin; HER2V777L Tg AdCre organoids
relative to organoids only expressing HER2V777L, suggesting a role for HER2V777L expression on
Wnt signaling pathway activation in the context of APC loss. Overall, we determined that the
expression of APC and HER2 mutations enhances expression of a Wnt-target gene, c-Myc, as a
possible mechanism for enhanced growth. Future work will assess RNA expression differences
among these organoid lines using bulk-RNA sequencing.

Figure 2.9 qPCR analysis of HER2V777L Tg and APCmin; HER2V777L Tg organoid lines
Relative expression of c-Myc mRNA using RNA isolated from intestinal organoid lines grown in
ENR media for five days. Representative data from 2 technical replicates. ∗P < .05 by Student ttest.
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2.6 Discussion
Overall, we have determined the role of HER2 and APC mutations on cell proliferation,
downstream signaling pathways, and cell morphology using an intestinal organoid culture model.
These studies are the first to illustrate the role of the activating HER2V777L mutation on intestinal
epithelial proliferation using an intestinal organoids. We determined that HER2V777L expression
increased budding, enhanced proliferation within budded regions, and conferred resistance to a
MEK inhibitor, TAK-733 (Figure 2.10).
Previous studies exploring the role of other EGFR family members, such as HER3, on organoid
morphology have determined that HER3 knock-out intestinal organoid cultures morphologically
resemble WT cultures in size, growth rates, and budding rates (86). In contrast, our studies
illustrate a role for HER2V777L on growth and proliferation, which is observed via enhanced
budding of our intestinal organoid cultures. Our results suggest that the budding phenotype is
due to enhanced proliferation and activation of pro-growth signaling pathways. HER2V777L
expression was also found to confer resistance to MEK inhibitors, which underscores a greater
need to understand how to best target HER2mutant colorectal cancers.
We also determined the role of APC and HER2 co-occurring mutations using our intestinal
organoid culture model. Previous studies have determined that APC and KRAS double mutant
organoids form cystic structures in culture and form liver metastases when transplanted
subcutaneously (87). In our organoid culture model, we determined that APCmin; HER2V777L Tg
AdCre organoids possessed enhanced budding, expanded proliferation zones, and enhanced cMyc expression via qPCR analyses. The abnormal budding phenotype observed in our APCmin;
HER2 Tg cultures is likely due to increased proliferation conferred by HER2V777L expression.
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These preliminary studies would also benefit from RNA sequencing analysis to determine which
genes are upregulated in response to HER2 or APC mutations in our organoid culture model.
Future work will utilize in vivo models to further determine the impact of HER2 and APC
mutations on the crypt-villus architecture of the intestinal epithelium and tumorigenesis. Overall,
we demonstrated an initial characterization of the role of both HER2 and APC mutations and
determined a crucial role for HER2V777L on intestinal epithelial proliferation and growth.

Figure 2.10 Summary of HER2V777L Tg and APCmin; HER2V777L Tg organoid model
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Chapter 3: HER2 and APC mutations promote altered crypt
morphology and marked hyperplasia in the intestinal epithelium
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This chapter was adapted from:
Murray E, Krishna A, Ohara T, Stappenbeck T, and Bose R. (2020) HER2 and APC
mutations promote altered crypt-villus morphology and marked hyperplasia in the
intestinal epithelium. Submitted to the journal of Cellular and Molecular Gastroenterology
and Hepatology.
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3.2 Abstract
Colorectal cancer patients possess co-occurring HER2 and APC mutations. Here, we
investigated the role of HER2 and APC mutations on the crypt-villus architecture of the
intestinal epithelium, localization of secretory cells, and expression of intestinal stem cell
markers. We generated a HER2 transgenic mouse (HER2V777L Tg) possessing an activating
mutation commonly found in colorectal cancer patients, HER2V777L, using TALEN based gene
editing technology. We determined that HER2V777L expression resulted in hypertrophic crypt
formation with expanded zones of proliferation, hyperplasia, and mis-localized Paneth cells.
Additionally, we determined that HER2 and APC mutations, when combined, promote enhanced
proliferation of intestinal crypts and these mutations play an early role during tumorigenesis.
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3.3 Introduction
The intestinal epithelium is tightly regulated by the expression of several growth factors
produced within the stem cell niche that control intestinal cell proliferation and differentiation.
For example, members of the epidermal growth factor receptor family (EGFR, HER2, HER3,
and HER4) are commonly expressed throughout the intestinal epithelium and regulate cell
migration, survival, and differentiation (88). Furthermore, overexpression of these receptor
tyrosine kinases is known to result in poor outcomes in several gastric and other solid tumor
types (89-90). Further study of these receptor tyrosine kinases is needed to delineate their role in
cancer development.
HER2 mutations or alterations are known to have functional significance in colorectal cancer
development (33). For example, in vitro characterization of HER2 mutations has identified
several activating mutations, such as V777L and V842I that activate downstream signaling
pathways in colon cancer cell lines and confer anchorage-independent growth in soft agar assays
(37). As a result, HER2 mutations are thought to play a crucial role in cancer development,
however, the precise role that these mutations play on the intestinal epithelium has not been
determined.
Prior studies on other EGFR family members, such as HER3, have identified that expression of
these receptors play crucial roles in wound healing following chemically induced colitis,
tumorigenesis, and differentiation of secretory cell types, such as Paneth cells (91-93). Paneth
cells have been identified as crucial for maintenance of the stem cell niche and dysregulation of
Paneth cells are observed in the inflammatory bowel diseases, which are pre-malignant
conditions. Although the role of HER3 on the intestinal epithelium is well-defined, the role of an
activating HER2 mutation on intestinal epithelial architecture has not been characterized. As a
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result, we sought to determine the role of an activating HER2 mutation, HER2V777L, on the cryptvillus architecture of the intestinal epithelium. Furthermore, we also sought to examine the role
of HER2V777L on tumor formation and CRC progression using an APCmin mouse model.
We demonstrated that in vivo expression of HER2V777L resulted in hyperplasia, expansion of
intestinal crypts, and mislocalization of Paneth cells. Furthermore, HER2V777L expression, in the
context of APC loss, further enhanced proliferation of small intestinal crypts. These data provide
the first test of HER2V777L expression on intestinal epithelial homeostasis and provides further
insight into the role of HER2V777L on CRC tumorigenesis.
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3.4 Methods
Mice
Generation of transgenic mice expressing HER2V777L in the intestinal epithelium
HER2V777L transgenic mice (HER2V777L Tg) were generated using TALEN based genome
editing. ROSA26 specific TALENs were designed using the ZiFit targeter (94). The TALEN kit
used for TALEN assembly was a gift from Keith Joung (Addgene kit # 1000000017). DNA
fragments encoding ROSA TALEN repeat arrays were cloned into plasmid pJDS71. ROSA
TALENs plasmids were linearized for in vitro transcription with EcoRI and TALENs RNA was
synthesized using the mMessage mMachine T7 Ultra kit (Ambion) and purified with Megaclear
columns (Ambion).

The cassette of interest was synthesized (Genscript) and introduced into the mouse genome via
pronuclear injection of in vitro transcribed TALENs RNA and ROSA donor DNA. Founders
with correctly targeting mutant alleles are identified using long PCR with ROSA specific oligos
outside of the homology arms. Founders are mosaic with multiple mutant alleles and are bred to
WT to generate heterozygous F1 offspring. Analysis of F1 offspring via long PCR confirms
germline transmission of the correctly targeted allele. Primers for genotyping heterozygous
offspring are:
ROSA-green-WT-F1: 5’ GTT ATC AGT AAG GGA GCT GCA GTG GAG TAG 3’
ROSA-green-WT-R1: 5’ CCG AAA ATC TGT GGG AAG TCT TGT CCC TCC 3’
CAG-R2: 5’ CTC CAC CCA TTG ACG TCA ATG GAA AGT CCC 3’
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Lgr5-Cre ERT2 and Villin-Cre ERT2 mice
Lgr5-EGFP-Ires-CreERT2 mice were purchased from Jackson Laboratory (B6.129P2Lgr5tm1(cre/ERT2)Cle/J; 008875) and Villin-Cre ERT2 mice were a gift from Blair Madison and are
also available from the DDRCC core (95). APCmin mice were also purchased from Jackson
Laboratory (C57BL/6J-ApcMin/J; 002020). All animal work was approved by the Washington
University School of Medicine Animal Studies Committee.
Induction of recombination
Expression of the transgene was driven by Cre-recombination of the lox-stop-lox sites. We
crossed HER2V777L Tg mice to Lgr5-EGFP-IRES-CreERT2 or Villin-CreERT2 mice to activate
HER2 expression in intestinal stem cells or the intestinal epithelial cells, respectively. To study
the contribution of APC loss on the intestinal epithelium, Lgr5-Cre; HER2V777L Tg mice were
crossed with heterozygous APCmin mice to generate Lgr5-Cre; APCmin; HER2V777L Tg mice.
For CreERT2-mediated recombination, 8-9 week old mice were injected intraperitoneally with
tamoxifen (2 mg/injection; Sigma-Aldrich, St. Louis, MO) dissolved in corn oil for three
consecutive days and sacrificed 10 days after the last tamoxifen injection.
Immunohistochemistry of paraffin-embedded sections
The proximal small intestine, distal small intestine, and colon were embedded in 2% agar,
paraffin embedded, and 5 µm sections were prepared (Digestive Diseases Research Core,
Washington University School of Medicine). For histology, unstained slides were stained for the
indicated antibodies via immunohistochemistry (Department of Immunology and Pathology,
Washington University School of Medicine). Immunohistochemistry was performed by a
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standard protocol on Ventana automated stainer (Ventana Medical Systems, Tucson, AZ, USA).
Antigen retrieval was performed for HER2 /neu (rabbit monoclonal, clone 4B5) (Ventana) with
CC1 buffer (Cell Conditioning 1; EDTA-based buffer pH 8.0, Ventana), for KI-67 2 ug/mL
(rabbit monoclonal, clone 30-9 )(Ventana) with CC1 buffer (Cell Conditioning 1; EDTA-based
buffer pH 8.0, Ventana) for Lysozyme (rabbit polyclonal) (Cell Marque) with CC1 buffer (Cell
Conditioning 1; EDTA-based buffer pH 8.0, Ventana).
Biotin-free multimer technology system, based on direct linkers between peroxidase and
secondary antibodies (ultraView Universal DAB Detection Kit, Ventana Medical System) were
used as detection kit.
Immunofluorescence of paraffin-embedded sections
Slides were de-paraffinized and subjected to heat-induced antigen retrieval in Trilogy
(MilliporeSigma) solution for 20min. Slides were blocked in PBS containing 1% BSA, 5% goat
serum and 0.1% Triton-X 100 for 1hr at room temperature, and then treated with primary
antibodies at desired dilutions for 16 hours at 4°C. Slides were then washed 3 times in PBS and
incubated with secondary antibodies conjugated with fluorophores (Thermo Fisher Scientific) for
1 hour at room temperature (96).
Establishment of intestinal organoid cultures
Isolation of crypts from the jejunum of Lgr5-Cre; HER2V777L Tg and HER2V777L Tg littermate
mice were performed as described (72) and as listed in chapter 2. Isolated intestinal crypts were
embedded in Matrigel (BD Biosciences) and seeded in 6-well plates. The cells were overlaid
with 2 mL/well basal culture medium (advanced Dulbecco’s modified Eagle medium/F12
39

supplemented with penicillin/streptomycin, 10 mmol/L HEPES, Glutamax, 1 × N2, 1 × B27 [all
from Thermo Fisher Scientific], and containing EGF (Sigma), noggin, and Rspo1 (Noggin and
R-spondin conditioned media were a gift from Blair Madison).
Transmission Electron Microscopy
For ultrastructural analyses, samples were fixed in 2% paraformaldehyde/2.5% glutaraldehyde
(Polysciences Inc., Warrington, PA) in 100 mM sodium cacodylate buffer, pH 7.2 for 2 hr at
room temperature and then overnight at 4C. Samples were washed in sodium cacodylate buffer
at room temperature and postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 hr. Samples
were then rinsed extensively in dH20 prior to en bloc staining with 1% aqueous uranyl acetate
(Ted Pella Inc., Redding, CA) for 1 hr. Following several rinses in dH20, samples were
dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.).
Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc.,
Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX
transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8
megapixel digital camera and AMT Image Capture Engine V602 software (Advanced
Microscopy Techniques, Woburn, MA).
Quantitative Reverse Transcription (RT)-PCR (qRT-PCR)
RNA was isolated from the jejunum of the Lgr5-Cre; HER2V777L Tg mice and 2 ug of RNA were
reverse transcribed into cDNA using the cDNA reverse transcription kit (Applied Biosystems,
Foster City, CA). qRT-PCR was performed with a ABI Prism 7300 Sequence Analyzer using
SYBR green fluorescence probes. Quantification cycle (Cq) of genes of interest were normalized
to the average Cq of 18s ribosomal RNA (reference gene) and expressed as relative mRNA
levels. Primers were a gift from Matt Ciorba and primer sequences are listed below (97).
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Primer name
18s F
18s R
mLgr5 F
mLgr5 R
mLrig1 F
mLrig1 R
mAlpi F
mAlpi R
mAtoh1 F
mAtoh1 R
mMuc2 F
mMuc2 R
mChgA F
mChgA R
mLyz F
mLyz R
mDefcr5 F
mDefcr5 R
mAxin2 F
mAxin2 R
mOlfm4 F
mOlfm4 R
mBmi1 F
mBmi1 R
mSI F
mSI R
mAlpi F
mAlpi R

Primer sequence
GTAACCCGTTGAACCCCATT
CCATCCAATCGGTAGTAGCG
TGCCCATCACACTGTCACTGT
CACCCTGAGCAGCATCCTG
TTGAGGACTTGACGAATCTGC
CTTGTTGTGCTGCAAAAAGAGAG
AGGACATCGCCACTCAACTC
GGTTCCAGACTGGTTACTGTCA
GGGGTTGTAGTGGACGAGC
CGTTGTTGAAGGACGGGATAAC
ATGCCCACCTCCTCAAAGAC
GTAGTTTCCGTTGGAACAGTGAA
CCAAGGTGATGAAGTGCGTC
GGTGTCGCAGGATAGAGAGGA
GAGACCGAAGCACCGACTATG
CGGTTTTGACATTGTGTTCGC
AGGCTGATCCTATCCACAAAACAG
TGAAGAGCAGACCCTTCTTGGC
AACCTATGCCCGTTTCCTCT
CTGGTCACCCAACAAGGAGT
GCCACTTTCCAATTTCAC
GAGCCTCTTCTCATACAC
CCAATGAAGACCGAGGAGAA
TTTCCGATCCAATCTGCTCT
GCTATCGCTCTTGTTGTGGTT
TTCCAGGACTAGGGGTTGAAG
AGGACATCGCCACTCAACTC
GGTTCCAGACTGGTTACTGTCA

Genomic analysis of ERBB2 and APC co-occurring mutations
Mutations were extracted from TCGA Unified Ensemble MC3 Call Set (98). Colon
Adenocarcinoma (COAD) or Rectum Adenocarcinoma (READ) patients were extracted from the
MC3 mutation file resulting in a total of 559 patients with 223860 mutations (excluding the
following mutation types: Silent, Intron, RNA, 5’ Flank, 3’ flank, IGR, Translation Start Site, 3’
UTR and 5’ UTR).
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Statistical analysis
Data are presented as means and SEM. The Student t test was used to analyze data with 2 groups.
For statistical analysis, GraphPad Prism (version 7; GraphPad Software, Inc, La Jolla, CA) was
used. A P value less than .05 was considered statistically significant. All authors had access to
the study data and reviewed and approved the final manuscript.
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3.5 Results
HER2V777L expression driven by Lgr5-CreERT2 enhances crypt depth and villus length
HER2 transgenic mice expressing the Lox-STOP-Lox HER2 V777L transgene (HER2V777L Tg)
were generated using TALEN based gene editing (Figure 3.1A). The HER2 V777L mutation is a
constitutively activated mutation that has been identified in human colorectal cancer patients
(37). Since colorectal cancer arises from intestinal stem cells, we utilized the Lgr5-CreERT2
mouse strain, which expresses Cre-recombinase in the Lgr5-positive crypt-base columnar stem
cells to activate HER2V777L expression (99-100).
To assess the role of HER2V777L expression on the intestinal epithelium, two-month old Lgr5Cre; HER2V777L Tg and littermate control mice were treated with tamoxifen for 3 consecutive
days and sacrificed 10 days after the last injection (Figure 3.1B). HER2V777L expression resulted
in hypertrophic crypt formation throughout the proximal small intestine, distal small intestine,
and colon relative to littermate control mice (Figure 3.1C-E). In the mucosal folds of the
proximal colon, HER2V777L expression also triggered remodeling of the epithelium with fingerlike projections resembling villi, which were not observed in the colon of control mice (Figure
3.1E). The observed hypertrophic phenotype was also illustrated by increased crypt depth in
Lgr5-Cre; HER2V777L Tg mice in the proximal small intestine, distal small intestine, and colon by
1.4, 1.8, and 2.6-fold, respectively (Figure 3.1F, respectively). HER2V777L expression also
increased the number of Ki-67 positive cells by 2.2, 1.9, and 1.9-fold in the proximal small
intestine, distal small intestine, and colon, respectively (Figure 3.1G). Lastly, HER2V777L
expression also increased villus length in the proximal and distal small intestine by 1.8 and 1.6fold, respectively, relative to control mice (Figure 3.1H-I). These findings demonstrate that
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HER2V777L expression resulted in pronounced hypertrophic crypt formation characterized by
enhanced proliferation and increased height of intestinal villi.
Next, to determine whether the enhanced growth phenotype observed in vivo is epithelial cellintrinsic or cell-extrinsic, we utilized small intestinal organoid cultures. We generated organoids
from Lgr5-Cre; HER2V777L Tg mice and observed changes in morphology conferred by
HER2V777L expression. Lgr5-Cre; HER2V777L Tg organoids possessed larger buds after growth in
EGF, Noggin, and R-spondin media for 5 days relative to littermate control organoids, which
correlated with the enhanced crypt size observed in vivo (Figure 3.1J).
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Figure 3.1: HER2V777L expression confers hypertrophic crypt formation in vivo and in vitro
(A) Schematic for design of HER2V777L transgenic mouse. (B) Lgr5-Cre; HER2V777L and
HER2V777L littermate mice were treated with tamoxifen for 3 consecutive days and sacrificed 10
days after the last injection. (C-E) H&E, HER2, and Ki-67 images of proximal, distal, and colon
tissue sections from Lgr5-Cre; HER2V777L Tg and littermate control mice. Scale bars are 50 µm.
(F) Quantification of crypt depth for proximal small intestine, distal small intestine, and colon as
measured in micrometers. Eighty crypts per mouse were measured and n ≥ 3 per group. (G)
Quantification of Ki-67 positive cells per crypt. (H) H&E and HER2 staining of Lgr5-Cre;
HER2V777L Tg and littermate control villi. Scale bars are 100 µm. (I) Quantification of villus
length for proximal and distal small intestine. Eighty villi per mouse were measured and n=3 per
group. (J) Representative image of small intestinal organoids generated from the jejunum of
Lgr5-Cre; HER2V777L Tg and control mice grown for 5 days in EGF, Noggin, and R-spondin
media. Scale bars are 500 µm. Data are plotted as means, 1 dot represents 1 mouse and means ±
SEM are reported. ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001 as calculated by Student t test.
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HER2V777L expression reduces intestinal stem cell populations and increases expression of
absorptive markers
Due to the enhanced crypt size observed in vivo, we next examined whether expression of
intestinal stem cell markers were altered using qRT-PCR. Expression of the stem cell markers,
Olfm4, and Lgr5, were reduced by 3.9 and 3.1-fold, respectively, in Lgr5-Cre; HER2V777L Tg
mice relative to control mice, whereas no significant differences were observed in the expression
of Lrig, a negative regulator of EGFR signaling. Interestingly, HER2V777L expression increased
expression of the +4 stem cell marker, Bmi1, by 1.8-fold relative to littermate control mice
(Figure 3.2A). To determine whether the loss of intestinal stem cells observed was due to
decreased Wnt signaling, we also examined expression changes of Wnt target genes such as cMyc and Axin2 (Figure 3.2B). Although changes in c-Myc expression were not observed, Axin2
expression was reduced by 2.1-fold in Lgr5-Cre; HER2V777L Tg mice relative to littermate
control mice. Taken together, our data suggest that HER2V777L expression reduces Wnt signaling
to decrease the stem cell population in the crypt compartment. The increased expression of
Bmi1, however, suggests that secretory progenitors are still able to persist. As a result,
HER2V777L expression enlarges crypt size while reducing the intestinal stem cell population.
HER2V777L expression promotes enhanced expression of absorptive markers and Paneth
cell mislocalization
Given the differences observed in the stem cell population of Lgr5-Cre; HER2V777L Tg mice, we
next sought to examine whether epithelial differentiation was altered using qRT-PCR. The
Paneth cell marker, Defcr5, was reduced by 7.3-fold relative to control mice, whereas expression
of Muc2, a goblet cell marker, was enhanced by 2.9-fold in Lgr5-Cre; HER2V777L Tg mice.
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Significant differences in Chromogranin A or Lysozyme expression were not observed (Figure
3.2C). Additionally, expression of Atoh1, a transcription factor required for secretory cell
differentiation, was not significantly decreased in Lgr5-Cre; HER2V777L Tg mice. Interestingly,
expression of the absorptive markers, Fabp1 and Alpi, was increased by 7.6 and 20.9-fold,
respectively, in Lgr5-Cre; HER2V777L Tg mice (Figure 3.2D). Overall, our data suggests that
HER2V777L expression promotes goblet cell hyperplasia and enhanced expression of absorptive
markers, which may due to the increased villus height observed in our transgenic mouse model.
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Figure 3.2: HER2V777L expression reduces intestinal stem cell populations and increases
expression of absorptive markers
Small intestinal tissue from Lgr5-Cre; HER2V777L Tg and littermate control mice were examined
for the expression of (A) stem cell markers, (B) Wnt target genes, (C) secretory cell markers, and
(D) absorptive markers via qRT-PCR. 18s ribosomal RNA was used as a reference gene. n=3
mice per genotype. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001 as calculated by
Student t test. mRNA, messenger RNA. ns., not significant.

47

HER2V777L expression promotes Paneth cell mislocalization and goblet cell hyperplasia
To determine whether the expression changes observed by qRT-PCR could be detected at the
protein level, we utilized immunohistochemistry to assess Paneth, goblet, and absorptive cells in
our transgenic mouse model. Paneth and goblet cell number per crypt decreased by 2.6 and 1.5fold, respectively, as assessed by Lysozyme and Periodic-Acid Schiff staining, relative to
littermate control mice (Figure 3.3A and 3.3B-C). Lgr5-Cre; HER2V777L Tg mice also possessed
a 2-fold increase in enterocytes as assessed by Fabp1 staining (Figure 3.3A and D), which
correlated with the mRNA expression data shown in Figure 3.2D. Due to the decrease of Paneth
cells observed in Lgr5-Cre; HER2V777L Tg mice, we assessed structural changes in Paneth cell
granules using transmission electron microscopy (TEM). For this analysis, we utilized VillinCre; HER2V777L Tg mice due to the mosaicism of the Lgr5-Cre mouse strain. In Villin-Cre;
HER2V777L Tg mice, Paneth cell granules appeared enlarged and reduced in number via TEM
relative to littermate control mice (Figure 3.3E).
Interestingly, although Paneth and goblet cells were reduced per crypt, an increased number of
Paneth cells were located along the villus instead of the crypt, and goblet cell number per villus
was increased in Lgr5-Cre; HER2V777L Tg mice by 3 and 1.6-fold, respectively (Figure 3.3F-H).
Morphologically, the paneth cells observed on the villus resembled goblet cells, indicating that
these cells may be intermediate cells, possessing both Paneth and goblet cell characteristics. As a
result, we determined that HER2V777L expression promotes mis-localization of Paneth cells on
intestinal villi and goblet cell hyperplasia.
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HER2V777L expression down-regulates E-cadherin to promote Paneth cell mislocalization
Due to the mis-localization of Paneth cells observed in Lgr5-Cre; HER2V777L Tg mice, we sought
to determine possible mechanisms underlying the observed phenotype. Prior research has shown
that E-cadherin loss throughout the intestinal epithelium promotes Paneth cell mis-localization
along the villus (101). Additionally, HER2 expression has been previously shown to downregulate E-cadherin expression in breast epithelium (102). As a result, we utilized
immunofluorescence to determine if E-cadherin expression was decreased in our HER2V777L Tg
mouse. A reduction in E-cadherin staining along the villus in the Lgr5-Cre; HER2V777L Tg mice
was observed in contrast to littermate control mice (Figure 3.3I). The pattern of E-cadherin
staining was also disrupted in Lgr5-Cre; HER2V777L Tg mice. As a result, the Paneth cell mislocalization may be due to reduced E-cadherin expression in the intestinal epithelium.
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Figure 3.3: HER2V777L expression decreases Paneth cell number per crypt and promotes
Paneth cell mis-localization
(A) IHC staining for Lysozyme, Periodic Acid-Schiff (PAS), and Fabp1, respectively of Lgr5Cre; HER2V777L Tg and littermate control mice (proximal small intestine). Scale bars are 50 µm.
(B) Quantification of Paneth cell number per crypt, (C) PAS positive cells per crypt, and (D)
Fabp1 positive cells per crypt. Eighty crypts were measured from the proximal small intestine
and n= 3 per group. (E) Transmission electron microscopy (TEM) for Paneth cell granules in
Villin-Cre; HER2V777L Tg and littermate control mice. Scale bars are 2 µm. (F) IHC staining for
Lysozyme and PAS on intestinal villi in the proximal small intestine. Scale bars are 100 µm. (G)
Quantification of Paneth cell number per villus and (H) Quantification of PAS positive cells per
villus in the proximal small intestine. Eighty intestinal villi were measured and n=3 per group. (I)
Immunofluorescence staining for E-cadherin in littermate control and Lgr5-Cre; HER2V777L Tg
mice. Scale bars are 100 µm in left panel and 50 µm in right panel. Representative images are
shown. Data are plotted as means, 1 dot represents 1 mouse and means ± SEM are reported.
∗∗P < .01, and ∗∗∗P < .001 as calculated by Student t test.

50

HER2V777L expression alters Paneth cell granules and adenoma localization
Next, we sought to examine the role of co-occurring mutations on tumorigenesis using our
HER2V777L transgenic mouse model. Colorectal cancer patients possessing HER2 missense
mutations possess several co-occurring alterations in tumor suppressor genes such as APC,
TP53, and oncogenes such as, KRAS and PIK3CA (98) (Figure 3.4). Of these co-occurring
mutations, we sought to examine the role of both HER2 and APC mutations on tumor
progression using an APCmin mouse model. Lgr5-Cre; HER2V777L Tg mice were crossed with
heterozygous APCmin mice to generate Lgr5-Cre; APCmin; HER2V777L Tg mice and intestinal
adenomas relative to Lgr5-Cre; APCmin control mice were analyzed via immunohistochemistry
staining. Surprisingly, HER2V777L expression did not result in significant increases in the number
of Ki-67 positive cells per adenoma, average adenoma size or adenoma number per mouse
(Figure 3.5A-D). Interestingly, Lgr5-Cre; APCmin; HER2V777L Tg mice possessed several hyperproliferative regions characterized by proliferative crypts that protrude towards villus tips
(Figure 3.5E). These hyper-proliferative regions were not observed in Lgr5-Cre; APCmin control
mice. To assess morphological changes in Paneth cells, which are mis-localized throughout
adenomas, we utilized TEM analysis of Lgr5-Cre; APCmin; HER2V777L Tg mice. TEM identified
abnormal Paneth cell granules with large vacuoles containing fibrous material, indicating that
HER2V777L expression may also disrupt Paneth cell morphology (Figure 3.5F). Overall, we
determined that HER2 and APC mutations promote a hyper-proliferative environment that may
promote a tumor initiating phenotype rather than tumor progression. Mutations in other tumor
suppressors and oncogenes are likely needed to observe cancerous phenotypes.
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Figure 3.4-Heat-map of co-occurring mutations in HER2mutant colorectal cancer patients
Colon Adenocarcinoma (COAD) or Rectum Adenocarcinoma (READ) patients were extracted
from the TCGA Unified Ensemble call set resulting in a total of 559 patients. All COAD (blue)
and READ (light blue) patients found to have Missense Mutations in ERBB2 that co-occur with
any other mutation type in a subset of genes are highlighted on the left. A green box indicates at
least one mutation was identified in the patient of interest labeled on the x axis. ERBB2 and APC
co-occurring mutations are highlighted (black box).
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Figure 3.5-HER2V777L expression promotes hyper-proliferation in the context of APC loss
(A) IHC staining for HER2 and Ki-67 in intestinal adenomas of Lgr5-Cre; APCmin; HER2V777L
Tg and Lgr5-Cre; APCmin mice. Scale bars are 100 µm. (B) Quantification of the average number
of Ki-67 positive cells per adenoma (proximal and distal small intestine). n=3 per group. (C)
Average adenoma size per mouse as measured in micrometers (proximal and distal small
intestine). n≥ 3 per group. (D) Quantification of adenoma number per mouse (proximal and distal
small intestine). n=3 per group. (E) IHC staining for HER2 and Ki-67 in hyper-proliferative
crypts. Scale bars are 100 µm. (F) TEM analysis of Paneth cell granules in Lgr5-Cre; APCmin;
HER2V777L Tg and Lgr5-Cre; APCmin mice. Scale bars are 2 µm in all images except lower right
(500 nm). Representative images are shown. No significant differences measured by Student ttest in B-D.

53

3.6 Discussion
This work is the first to characterize the role of HER2V777L expression on the intestinal
epithelium using transgenic mice. We hypothesized that expression of HER2V777L would promote
crypt hyperplasia and enhanced proliferation due to the role of HER2 and other EGFR family
members on cell growth and proliferation using in vitro models (36, 103). Using our transgenic
mouse model, we determined that HER2V777L expression increased crypt depth and villus height
via enhanced proliferation (Figure 3.6). Interestingly, HER2V777L expression was also found to
decrease expression of intestinal stem cell markers, such as Olfm4 and Lgr5. Prior research has
attributed stem cell loss to decreased expression of Wnt target genes, and a similar phenotype
was observed in our transgenic mouse model (104). Furthermore, HER2V777L expression also
resulted in Paneth cell loss per crypt, and Paneth cell loss also likely contributed to the reduction
of stem cells and Wnt signaling observed, however, further studies are needed to determine the
underlying mechanism.
We also assessed the role of HER2V777L expression on secretory and absorptive lineages using
our transgenic mouse model. Notch signaling is responsible for cell fate determination between
the absorptive and secretory lineage and hyperactive Notch signaling results in decreased Atoh1
expression, hyper-proliferation, and increased numbers of enterocytes (105). Interestingly, in our
HER2V777L Tg mouse model, we did not observe significant differences in Atoh1 expression,
however, HER2V777L expression promoted goblet cell hyperplasia and increased expression of
absorptive markers. The secretory and absorptive phenotype observed may be due to hyperproliferation in our model, which enhances villus height leading to increased numbers of goblet
cells and enterocytes. Further analysis of Notch signaling pathway components will be needed to
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determine the role of HER2V777L expression on secretory cell determination. We also observed a
striking phenotype in which Paneth cells were mis-localized on the villus and this phenotype was
likely due to reduction of E-cadherin, which is known to contribute to Paneth cell localization in
the intestinal epithelium (101). In summary, we determined that HER2V777L expression promotes
crypt hyperplasia, intestinal stem cell loss, and altered Paneth cell localization (Figure 3.6).
Limitations to our model include a short time frame (10 days) between the last tamoxifen
injection and tissue analysis of our Lgr5-Cre; HER2V777L Tg mice. Longer time points following
tamoxifen injection could examine changes in the observed phenotypes over time. Additionally,
we acknowledge that our model illustrates overexpression of an activating HER2V777L mutation,
which could produce severe phenotypes not observed in a knock-in model, however, both
overexpression of HER2 and HER2 mutations are observed in colorectal cancer patients (37).
Lastly, our studies to examine the role of HER2 and APC mutations on tumorigenesis illustrated
that HER2V777L expression lead to a hyper-proliferative phenotype in Lgr5-Cre; APCmin;
HER2V777L Tg mice. Interestingly, we did not observe an increase in the number or size of
intestinal adenomas in Lgr5-Cre; APCmin; HER2V777L Tg mice relative to control mice.
Limitations to our tumorigenesis model include the age of mice and the duration of time between
tamoxifen injection and analysis of intestinal adenomas. Specifically, Lgr5-Cre; APCmin;
HER2V777L Tg mice were 9 weeks old at the time of analysis and these mice were sacrificed 10
days after the last tamoxifen injection. Significant differences in adenoma size and number may
be observed if the length of time was extended after tamoxifen injection. Additionally,
expression of our HER2V777L transgene might require additional mutations in tumor suppressor
genes and oncogenes for progression of benign adenomas to carcinomas.
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In summary, we determined that HER2V777L expression conferred hypertrophic crypt formation
and mis-localization of Paneth cells. Expression of both HER2 and APC mutations resulted in
enhanced proliferation of the crypt compartment (Figure 3.6). This work is the first to
characterize the role of HER2V777L on the intestinal epithelium and illustrates a critical role for
HER2V777L in the early stages of tumorigenesis. The striking phenotypes observed using the
HER2V777L transgenic mouse model also illustrates a need to study the role of oncogenes in early
cancerous lesions in order to better understand the underlying morphological changes associated
with colon cancer development.

Figure 3.6-Model of HER2 and APC mutations on the intestinal epithelium
HER2V777L expression conferred hypertrophic crypt formation characterized by loss of intestinal
stem cells and mis-localization of paneth cells along the villus. Additionally, HER2V777L
expression induced goblet cell hyperplasia and increased expression of absorptive cell markers.
Lastly, HER2V777L expression, in the context of APC loss, induced hyper-proliferation of the
crypt compartment.
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Chapter 4: Functional characterization of co-occurring mutations in
HER2 mutant colorectal cancer cell lines
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4.2 Abstract
In colorectal cancer patients, HER2 mutations confer resistance to a HER2/EGFR tyrosine
kinase inhibitor, neratinib, whereas HER2 mutant breast cancer patients are sensitive to
neratinib. Given the lack of response in colon cancer patients, we sought to determine various
mechanisms of resistance to neratinib, using colorectal cancer cell lines (CW-2 and CCK-81)
engineered to overexpress hotspot PIK3CA or KRAS mutations. We determined that expression
of the KRAS G12V mutation in the CW-2 and CCK-81 cells conferred resistance to neratinib
and enhanced MAPK phosphorylation. In contrast, the PIK3CA mutations did not have effect
neratinib sensitivity. Lastly, the JVE187 cell line, expressing endogenous HER2, KRAS, and
PIK3CA mutations, was resistant to neratinib, yet sensitive to PI3K inhibition. Our experiments
provide initial characterization of the role of co-occurring mutations on sensitivity to HER2
targeted therapeutics and downstream signaling pathways.
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4.3 Introduction
Mutation or over-expression of colorectal cancer driver genes often results in resistance to
targeted therapeutics. For example, expression of HER2 kinase domain mutations in colon cell
lines conferred reduced sensitivity to EGFR inhibitors, such as cetuximab, due to sustained
MAPK signaling. In contrast, HER2 mutations conferred sensitivity to dual HER2/EGFR
targeted therapy, such as neratinib in colon cell lines (37). However, a recent basket trial of
HER2 mutant tumors (breast, lung, colorectal, biliary) treated with neratinib identified tumor
shrinkage in breast and lung, however, HER2 mutated colorectal cancer patients did not respond
to neratinib (42). The lack of response observed was attributed to co-occurring mutations in the
RAS or PI3K signaling pathways and lineage dependent resistance.
In particular, mutations in KRAS and PIK3CA are known to hyper-activate the Ras/Raf/Mapk
and Akt signaling pathways, respectively. KRAS mutations, for example, commonly occur at
codons 12 or 13 (KRAS G12V/G13D), however, exon 4 non-hotspot mutations, such as K117N,
have also been identified in primary invasive colorectal tumors (106-107). In contrast, mutations
in PIK3CA are mainly located in the helical domain at codon 545 (exon 9) or the kinase domain
at codon 1047 (exon 20) in colorectal tumors (108). Previous studies using knock-in gene editing
of HER2 mutations in breast cancer cell lines have determined that combined expression of
HER2 and PIK3CA mutations enhances signaling pathway activation and migration (109).
However, the role of HER2 and co-occurring mutations on neratinib sensitivity using colorectal
cell lines containing endogenous HER2 mutations has not been determined. As a result, we
sought to examine mechanisms of resistance to neratinib using HER2 mutant colorectal cancer
cell lines.
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In this study, we determined the effect of mutations in common oncogenes, KRAS and PIK3CA
in the colorectal cancer cell lines, CW-2 and CCK-81, containing endogenous HER2 mutations.
We demonstrate that expression of a hotspot KRAS mutation decreased sensitivity to neratinib
and enhanced MAPK phosphorylation, whereas expression of a non-hotspot KRAS mutation
only conferred a modest effect in neratinib sensitivity. In contrast, PIK3CA mutations in our
colon cancer cell lines did not affect neratinib sensitivity. Lastly, we determined that the JVE187
cell line was resistant to neratinib and not dependent on HER2 expression for growth. These data
provide a possible rationale for the use dual-targeted therapy in HER2 mutated colorectal cancer
patients possessing both HER2 and KRAS mutations.
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4.4 Methods
Antibodies and Inhibitors
Antibodies for Western blots were purchased from Cell Signaling Technologies: phosphoEGFR
(Tyr1173), EGFR, phosphop44/42 MAPK (Thr202/Tyr204), p44/42 MAPK, phosphoAKT
(Ser473), and AKT; Millipore: phosphoHER2 (pY1248); and Thermo Fisher: HER2 antibody
(Ab-17). Neratinib was provided by Puma Biotechnology, Inc., under a Materials Transfer
Agreement. BEZ-235 and ONT-380 were obtained from SelleckChem.
Cell Lines
The CW-2 cell line was obtained from Riken BioResource Center and cultured in RPMI 1640
medium and supplemented with 10% FBS and 1% pencillin/streptomycin (P/S). The CCK-81
cell line was obtained from JCRB Cell Bank and cultured in EMEM supplemented with 10%
FBS and 1% pencillin/streptomycin (P/S). Both cell lines were maintained in a 5%
CO2 humidified atmosphere at 37 °C. The JVE187 cell line was obtained via Materials Transfer
Agreement from Tom Van Wezel in the Netherlands. JVE187 cells were cultured in RPMI-1640
supplemented with 10% FBS, 2 mM Glutamax-I, 50 U penicillin and 50 μg streptomycin per mL
(all from Life Technologies, Grand Island, NY, USA). Cells were cultured at 37°C.
Alamar blue assays
Inhibition of cell growth by neratinib, lapatinib, ONT-380, and BEZ-235 was measured by
Alamar blue assay (36). IC50 values were calculated by a 4 parameter nonlinear regression
conducted using SigmaPlot version 11 software (Systat software, Inc).
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Cloning and Retroviral Transduction of KRAS and PIK3CA Mutants in Colorectal Cancer
Cell Lines
The KRAS G12V plasmid was obtained from Addgene (pBabe-Puro-Kras*G12V) and sitedirected mutagenesis was utilized to generate the KRAS K117N mutant. PIK3CA E545K and
PIK3CA H1047R plasmids were also obtained from Addgene (16642 and 16639). The PIK3CA
constructs were cloned into the pCFG5 retroviral vector, which contains a zeocin resistance
marker and an IRES-GFP sequence, using the In-Fusion HD cloning system kit (Clontech,
Mountain View, CA).The desired constructs were verified using Sanger sequencing. Retroviral
particles were produced using φNX amphotrophic packaging cell line. PIK3CA or KRAS mutant
recombinant retroviral supernatants were transduced in CW-2 and CCK-81 cell lines as
described previously (37). Cell lines were subjected to 1-2 weeks of puromycin selection (KRAS
cell lines) or zeocin selection (PIK3CA cell lines) and transgene expression was verified by
western blot analysis for downstream targets.
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4.5 Results
Expression of PIK3CA E545K and H1047R mutations in CRC cell lines does not affect
neratinib sensitivity
Colorectal patients possess co-occurring mutations in HER2, KRAS, and PIK3CA, which often
results in poor sensitivity to targeted therapeutics (Figure 4.1). To determine the effect of cooccurring mutations on neratinib sensitivity using an in vitro model, we introduced the PIK3CA
E545K and H1047R mutations into the CW-2 cell line. This cell line contains an endogenous
HER2 L755S mutation as well as other mutations as listed in Table 4.1. We measured the effect
of these mutations on downstream signaling pathways and sensitivity to neratinib. The
aforementioned PIK3CA mutations were stably introduced into the CW-2 cells using a retroviral
vector. The introduction of the PIK3CA E545K mutation enhanced Akt phosphorylation and did
not affect phosphorylation of HER2 or HER3. The PIK3CA H1047R mutation modestly
enhanced Akt phosphorylation, and also did not alter phosphorylation of upstream receptors
(Figure 4.2A). Additionally, expression of either PIK3CA mutation did not alter sensitivity to
neratinib relative to the CW-2 parental cell line (Figure 4.2B). Overall, introduction of the
PIK3CA E545K or H1047R mutation primarily activates the Akt signaling pathway and as a
result, does not impact sensitivity to a HER2 targeted therapeutic. Our in vitro studies also
illustrate that the E545K mutation has a stronger effect on Akt phosphorylation than the H1047R
mutation in colon cancer cell lines.
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Figure 4.1 Summary of HER2 and co-occurring mutations in colon cancer patients.
Oncoprint of missense mutations (green) from 18 colorectal cancer patients/samples from the
Neratinib Basket Study (Hyman, 2018 (42)).

Table 4.1 Colon cancer cell line mutation summary

Figure 4.2 Neratinib sensitivity of CW-2 PIK3CA cell lines. (A) Western blot analysis of CW2 parental (control), CW-2 PIK3CA H1047R, and CW-2 PIK3CA E545K cell lines after
treatment with increasing doses of neratinib and (B) percent cell growth of CW-2 PIK3CA
mutant cell lines after treatment with neratinib for 6 days as measured via alamar blue assay.
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Introduction of a hotspot KRAS mutation decreases sensitivity to neratinib and gefitinib in
CRC cell lines
To explore the role of KRAS mutations on neratinib sensitivity using our colon cell line model,
we introduced the hotspot KRAS G12V mutation and non-hotspot KRAS K117N mutation into
the CW-2 and the CCK-81 cell lines using a retroviral vector. The CW-2 and CCK-81 cell line
express endogenous HER2 L755S and L720P mutations, respectively, and Kloth et al has shown
sensitivity of these cell lines to neratinib (39). The KRAS G12V mutation has been extensively
characterized as a gain-of-function mutation, whereas the KRAS K117N mutation has been
identified as a non-hotspot mutation that activates Ras-GTP, albeit to a lesser extent than hotspot
mutations (107).
Expression of the hotspot KRAS mutation, G12V, in the CW-2 cell line enhanced
phosphorylation of MAPK relative to the parental cell lines (Figure 4.3A). Additionally, HER2
phosphorylation was sustained after treatment with 100 nM neratinib in the KRAS G12V mutant
cell line. In contrast, expression of the KRAS K117N mutation resulted in a modest increase in
MAPK phosphorylation relative to CW-2 parental cells. Additionally, the introduction of the
KRAS G12V mutation resulted in a 5-fold change in neratinib sensitivity relative to CW-2
parental cells (Figure 4.3B) as measured by alamar blue assay. Expression of the KRAS K117N
mutation, however, did not change neratinib sensitivity.
Similarly, introduction of the KRAS G12V mutation in the CCK-81 cells enhanced MAPK
phosphorylation and mutant cells also possessed residual MAPK phosphorylation at high
neratinib concentrations, suggesting a potential resistance mechanism (Figure 4.4A).
Additionally, expression of the KRAS G12V and K117N mutation in the CCK-81 cell line
resulted in a 6 and 2.4-fold shift, respectively, in the neratinib IC50 (Figure 4.4B). Lastly, we also
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sought to determine the effect of KRAS mutations on sensitivity to gefitinib, an EGFR inhibitor.
We hypothesized that due to hyper-activation of downstream signaling pathways, KRAS mutant
cell lines would confer resistance to gefitinib. Expression of KRAS G12V or KRAS K117N
mutations conferred modest changes in gefitinib sensitivity (<2-fold) (Figure 4.5A). In contrast,
expression of KRAS G12V in the CCK-81 cell line conferred an 18-fold change in gefitinib
sensitivity relative to parental cells, whereas the expression of KRAS K117N conferred a 5.6fold change in sensitivity (Figure 4.5B). As a result, we determined that cell lines expressing
both HER2 and KRAS mutations also confer resistance to EGFR targeted therapeutics.
A CRC cell line derived from a liver metastasis is resistant to neratinib
We also assessed the sensitivity of another colorectal cancer cell line, JVE187, containing an
endogenous HER2 V842I mutation to neratinib. This cell line was of interest due to the presence
of endogenous co-occurring KRAS and PIK3CA mutations. As listed in table 4.1, this cell line
possessed the non-hotspot mutations, KRAS K117N as well as PIK3CA Q546K. Treatment of
the JVE187 cell line with increasing doses of neratinib did not impair cell growth with an IC50
greater than 250 nM (Figure 4.6A). Treatment of the JVE187 cells with other HER2 targeted
therapies such as lapatinib and ONT-380 also resulted in resistance. In contrast, JVE187 cells
were sensitive to PI3K inhibition with BEZ-235, which suggests that these cells were dependent
on PI3K for growth (Figure 4.6B). Overall, co-occurring mutations likely conferred resistance to
neratinib in the JVE187 cell line, however, further studies are needed to determine the
mechanism of resistance.
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Figure 4.3 Neratinib sensitivity of the CW-2 KRAS G12V and KRAS K117N cell lines. (A)
Western blot of CW-2 parental, CW-2 KRAS G12V, and CW-2 KRAS K117N cell lines after
treatment with increasing doses of neratinib and (B) percent cell growth of CW-2 KRAS mutant
cell lines after treatment with neratinib for 6 days as measured via alamar blue assay.

Figure 4.4 Neratinib sensitivity of the CCK-81 KRAS G12V and KRAS K117N cell lines.
(A) Western blot of CCK-81 parental, CCK-81 KRAS G12V, and CCK-81 KRAS K117N cell
lines after treatment with increasing doses of neratinib and (B) percent cell growth of CCK-81
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KRAS mutant cell lines after treatment with neratinib for 6 days as measured via alamar blue
assay.
A

B

Gefitinib (µM)

Gefitinib (µM)

Figure 4.5 Sensitivity of CW-2 KRAS mutant cell lines to gefitinib. (A) Dose response assays
of CW-2 KRAS mutant cell lines and (B) CCK-81 KRAS mutant cell lines after treatment with
gefitinib for 6 days at the indicated concentrations.

A

B

Figure 4.6 Response of JVE187 cell line to HER2 targeted therapeutics. (A) Percent cell
growth of JVE187 cell line after treatment with neratinib and (B) Lapatinib, ONT-380, and BEZ235 for 6 days as measured via alamar blue assay.
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4.6 Discussion
A recent basket trial on HER2 mutant cancers determined that HER2 mutant colon tumors were
resistant to HER2-targeted therapies, such as neratinib (42). Prior studies examining the effect of
HER2 amplification and co-occurring mutations in colon cell lines have determined that HER2
amplification confers resistance to EGFR monoclonal antibodies, whereas HER2 amplification
and PIK3CA mutations, when combined, confer sensitivity to MEK and PI3K combination
therapy (110). However, in vitro studies exploring endogenous HER2 mutations, instead of
HER2 amplification, and potential mechanisms of resistance in colon cell lines have not been
determined.
Here, we utilize a cell culture model to demonstrate the effect of HER2 and co-occurring
mutations on sensitivity to HER2 targeted therapy. Using colon cancer cell lines, we determined
that PIK3CA mutations in either the helical or kinase domain do not alter sensitivity to neratinib
and do not effect phosphorylation of upstream receptors. Prior studies in breast cancer cell lines
have also determined that the expression of HER2 and PIK3CA mutations do not change
sensitivity to a HER2 tyrosine kinase inhibitor, lapatinib, and confirm our results (109). PIK3CA
mutations likely primarily effect the Akt signaling pathway and do not alter expression of HER2
or HER3.
In contrast, we show that introduction of a hotspot KRAS mutation, G12V, decreases sensitivity
to neratinib in two colorectal cancer cell lines, CW-2 and CCK-81, expressing endogenous
HER2 mutations. In general, similar effects of the KRAS G12V mutation on neratinib sensitivity
were observed in the CW-2 and CCK-81 cell lines. Potential mechanisms underlying the
resistance observed include sustained activation of MAPK signaling after treatment with
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neratinib or up-regulation of HER2 or HER3 receptors as observed by western blot, however,
additional experiments need to be conducted to determine a precise mechanism. Additionally, we
also determined the role of a non-hotspot mutation, KRAS K117N, which has not been
extensively characterized, on sensitivity to HER2 or EGFR inhibitors. Prior research has
determined that this mutation enhances MAPK phosphorylation to similar levels observed in
hotspot mutations (107). We determined that expression of KRAS K117N conferred reduced
sensitivity to neratinib and gefitinib in the CCK-81 cell line, indicating that this mutation has
functional significance in our cell culture model. Lastly, we assessed the sensitivity of JVE187, a
cell line expressing HER2, KRAS, and PIK3CA endogenous mutations to HER2-targeted
therapies. The JVE187 cell line was resistant to neratinib, and the resistance observed in this cell
line was likely due to the presence of co-mutations in CRC driver genes.
Potential limitations of this study include the following. First, retroviral transduction of the
KRAS mutations into the CRC cell lines can produce overexpression of KRAS. However,
western blot analysis of total Ras protein levels relative to parental cells indicates the level of
overexpression is relatively modest in this system (data not shown). Second, we acknowledge
that other studies have examined the role of acquired KRAS mutations on sensitivity to EGFR
therapeutics in cell lines lacking HER2 mutations, however, this study examines the role of
HER2 and co-occurring mutations in colorectal cell lines. Lastly, we acknowledge that future
studies could benefit from in vivo xenograft assays to determine whether HER2 and KRAS
mutations enhance tumor formation.
In summary, this data suggests that patients possessing both HER2 and KRAS mutations could
benefit from therapies that target HER2 and MEK signaling due to the intracellular signaling
observed after treatment with neratinib. This work represents an initial characterization of the
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role of HER2 and co-occurring mutations on intracellular signaling pathways and sensitivity to
HER2-targeted therapeutics.
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Chapter 5: Conclusion and Future Directions
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5.1 Conclusion and Future Perspectives
The role of EGFR family of receptor tyrosine kinases on cancer development and progression
has been well studied. EGFR family members are expressed throughout the intestinal epithelium
and promote growth, proliferation, and maintenance of the intestinal stem cell niche. While prior
studies have examined the role of EGFR, HER3, and HER4 on proliferation, migration, and
Paneth cell development, the role of activating HER2 mutation, HER2 V777L, has not been
previously characterized in the intestinal biology field. In this work, we provide data that
enhances our understanding of HER2V777L expression on the intestinal epithelium, particularly,
the impact on intestinal cell proliferation and expression of secretory cells. In addition, we also
provide initial characterization of the role of HER2 and APC mutations on tumorigenesis.
We provide the first characterization of an activating HER2 mutation using various in vitro and
in vivo models. In chapter 2, we utilized an intestinal organoid culture model to examine the
effect of HER2 and APC mutations, alone or in combination, on organoid morphology,
intracellular signaling pathways, and expression of Wnt-target genes. Prior studies have
determined that expression of EGF in intestinal organoid culture media promotes enhanced
growth, however, studies of an activating HER2 mutation have not been published. Our results
suggest that expression of HER2V777L enhances budding of intestinal organoid cultures in an
EGF independent manner and combined mutation of HER2 and APC confers a budding
phenotype and activation of Wnt-target genes. These studies are crucial in further understanding
the role of HER2 and APC mutations on intestinal epithelial biology and their role in CRC
development.
The results generated from the intestinal organoid model represent an initial characterization of
HER2V777L expression on the intestinal epithelium, however, several questions remain
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unanswered regarding the phenotypes observed. First, the enhanced organoid budding due to
HER2V777L expression was hypothesized to be due to enhanced proliferation. However, the
specific genes underlying the enhanced growth phenotype have not been determined. RNAsequencing analysis of intestinal organoid cultures would therefore determine which genes in
several pathways are up or down-regulated as a result of HER2 and APC mutations.
Furthermore, it remains unclear whether the phenotypes observed are specific to the HER2
V777L mutation or represent a general effect of HER2 overexpression. Prior studies have not
examined the effect of different HER2 mutations, and additional in vitro studies using CRISPR
could aid in the understanding of how different mutations impact cell proliferation and
intracellular signaling pathways in an organoid culture model. Lastly, it remains undetermined if
HER2 and APC mutations, alone or in combination promote tumorigenesis in our organoid
culture model. Although HER2 expression in the context of APC loss, conferred increased
proliferation, it remains unclear if enhanced proliferation is sufficient for tumor formation. To
address this, future xenograft studies of HER2V777L and APCmin; HER2V777L organoid cultures
into nude mice would be helpful in examining tumor forming ability.
A main criticism of this work is the physiological relevance of HER2V777L expression levels in
our intestinal organoid model. In our model, human HER2V777L is overexpressed under the
control of a CAG promoter, which is known to result in high expression levels of the transgene.
We utilized this promoter to ensure that the transgene would be ubiquitously expressed in our
intestinal organoid model. In order to determine physiological relevance of our model, future
studies could compare expression of HER2V777L in our model to human colon tumor specimens
expressing HER2V777L to determine if expression levels are comparable. Additionally, human
colorectal cancer patients are known to possess both overexpression and mutation of HER2,
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which our mouse-derived organoid model depicts. Overall, the studies presented in chapter 2
delineate the role of HER2 or APC mutations on intestinal organoid growth and intracellular
signaling pathways.
Next, in chapter 3, we further explored the role of HER2 and APC mutations on the crypt-villus
architecture of the intestinal epithelium using our HER2V777L transgenic mouse model. In vivo
expression of HER2V777L, resulted in hyperplasia throughout the small intestine and colon, mislocalization of Paneth cells, and decreased expression of stem cell marker genes. Furthermore,
expression of HER2 and APC mutations, in combination, resulted in enhanced crypt
proliferation, however, adenoma size or number was not impacted. This work was crucial in
identifying a role of the activating HER2 V777L mutation on intestinal epithelial proliferation,
however, several questions regarding potential mechanisms remain unanswered.
First, the mechanism underlying the enhanced proliferation and hyperplasia has not been
determined. Future studies will utilize immunoblotting and RNA-sequencing analysis to identify
precise proteins and signaling pathways, such as Ras/MAPK or PI3K/Akt that are up-regulated
due to HER2V777L expression. Secondly, the phenotypes observed in vivo, such as loss of Paneth
cells, have not been re-capitulated using intestinal organoid cultures. As a result, future studies
will utilize immunofluorescence and qPCR analyses to determine if Paneth cell loss, intestinal
stem cell loss, and hyper-proliferation are also observed in intestinal organoid cultures. Small
intestinal organoid cultures will also be utilized to determine whether the Wnt or Notch signaling
pathways are up-regulated as a potential mechanism. Lastly, our model predominately illustrates
the role of HER2V777L on the small intestine, however, the HER2 V777L mutation is observed in
colorectal cancers. To increase the relevance of our model for colon cancer, future studies will
utilize mouse colon tissues derived from our HER2V777L transgenic mouse to examine the effect
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of HER2V777L expression on proliferation and crypt-depth in the colon. Furthermore, colon
organoids will also be generated from our HER2V777L transgenic mouse model to elucidate the
role of HER2V777L expression on organoid morphology, proliferation, secretory cell localization,
and expression of Wnt and Notch target genes. The addition of these studies will help to further
elucidate mechanisms responsible for the phenotypes observed in our Lgr5-Cre; HER2V777L Tg
mouse model.
Lastly, in chapter 4, we explored the role of co-occurring mutations on sensitivity to HER2targeted therapeutics using colon cell lines. Resistance to targeted therapeutics is known to be
mediated by the expression of oncogenic mutations or upregulation of receptors resulting in
hyper-activation of signaling pathways. Our data suggests that expression of HER2 and KRAS
mutations confer resistance to neratinib, a HER2/EGFR tyrosine kinase inhibitor via activation
of the MAPK signaling pathway. The data presented in this chapter confirm prior research of the
role of hotspot KRAS or PIK3CA mutations in breast cancer cell lines on sensitivity to HER2
targeted therapies. Our results also suggest that in addition to the known role of common KRAS
mutations, that non-hotspot mutations also confer reduced sensitivity to gefitinib and neratinib in
the CCK-81 cell line. Furthermore, characterization of the JVE187 cell line, a colon cancer cell
line with several endogenous oncogenic mutations, revealed that multiple non-hotspot cooccurring mutations impact sensitivity to HER2-targeted therapies. As a result, oncogenic
mutations, even at non-hotspot regions, impact cell response to therapeutics. To further elucidate
possible resistance mechanisms, future studies could also utilize transcriptomic analysis or RNA
expression analyses to uncover signaling pathways differentially effected by HER2 and KRAS
mutations alone or in combination. The main limitation of our model is the use of retroviral
transduction to introduce oncogenic mutations. These studies serve as an initial characterization
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of HER2 and co-occurring mutations, however, additional studies could utilize CRISPR to
generate genetically edited cell lines, which would result in a more physiologically relevant
model.
Overall, the work presented in this thesis, particularly in chapters 2 and 3, further elucidates the
role of an activating HER2 mutation, HER2 V777L, on the homeostasis of the intestinal
epithelium. Historically, EGFR family members are believed to not be essential for intestinal
homeostasis due to receptor redundancy. Instead, these receptors are thought to primarily play a
role during tumor progression. Interestingly, our work provides evidence for the first time that
expression of HER2V777L alters intestinal homeostasis by increasing intestinal epithelial cell
proliferation and enhancing crypt depth and villus height. In addition, this work also further
enhances our understanding of the contribution of co-occurring alterations on crypt proliferation,
which provides insight into changes that the intestinal epithelium may undergo prior to tumor
growth and progression. In summary, the studies presented here significantly enhance the current
understanding of the role of HER2V777L expression on the intestinal epithelium and the intestinal
biology field as a whole.
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